Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction

Charlotte B Holt; Steffen Thiel; Kim Munk; Jakob Appel Østergaard; Hans E Bøtker; Troels K Hansen

doi:10.1177/2048872613507004

Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction

Charlotte B Holt, Steffen Thiel, Kim Munk, Jakob Appel Østergaard, Hans E Bøtker, Troels K Hansen

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Many pathogenic processes and diseases are the result of an erroneous activation of the complement cascade and a number of inhibitors of complement have thus been examined for anti-inflammatory actions. It was recently demonstrated that supraphysiological concentrations of the endogenous complement inhibitor MAp44 (also denoted MAP1) protect against myocardial reperfusion injury. In the present study, we examined the association between outcome after acute myocardial infarction (MI) and the plasma levels of MAp44 and its related proteins MASP-1 and MASP-3 in patients with first-time MI. In addition, we compared plasma levels of MAp44, MASP-1, and MASP-3 in MI patients to levels in a healthy control group.

Originalsprog	Engelsk
Tidsskrift	European Heart Journal: Acute Cardiovascular Care
Vol/bind	3
Nummer	1
Sider (fra-til)	3-9
Antal sider	7
ISSN	2048-8726
DOI	https://doi.org/10.1177/2048872613507004
Status	Udgivet - 1 mar. 2014

Adgang til dokumentet

10.1177/2048872613507004

Citationsformater

@article{88ffe288812747d684b564502fbe3c95,

title = "Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction",

abstract = "Many pathogenic processes and diseases are the result of an erroneous activation of the complement cascade and a number of inhibitors of complement have thus been examined for anti-inflammatory actions. It was recently demonstrated that supraphysiological concentrations of the endogenous complement inhibitor MAp44 (also denoted MAP1) protect against myocardial reperfusion injury. In the present study, we examined the association between outcome after acute myocardial infarction (MI) and the plasma levels of MAp44 and its related proteins MASP-1 and MASP-3 in patients with first-time MI. In addition, we compared plasma levels of MAp44, MASP-1, and MASP-3 in MI patients to levels in a healthy control group.",

author = "Holt, {Charlotte B} and Steffen Thiel and Kim Munk and {\O}stergaard, {Jakob Appel} and B{\o}tker, {Hans E} and Hansen, {Troels K}",

year = "2014",

month = mar,

day = "1",

doi = "10.1177/2048872613507004",

language = "English",

volume = "3",

pages = "3--9",

journal = "European Heart Journal: Acute Cardiovascular Care",

issn = "2048-8726",

publisher = "SAGE Publications Ltd",

number = "1",

}

Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. / Holt, Charlotte B ; Thiel, Steffen ; Munk, Kim et al.
I: European Heart Journal: Acute Cardiovascular Care, Bind 3, Nr. 1, 01.03.2014, s. 3-9.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction

AU - Holt, Charlotte B

AU - Thiel, Steffen

AU - Munk, Kim

AU - Østergaard, Jakob Appel

AU - Bøtker, Hans E

AU - Hansen, Troels K

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Many pathogenic processes and diseases are the result of an erroneous activation of the complement cascade and a number of inhibitors of complement have thus been examined for anti-inflammatory actions. It was recently demonstrated that supraphysiological concentrations of the endogenous complement inhibitor MAp44 (also denoted MAP1) protect against myocardial reperfusion injury. In the present study, we examined the association between outcome after acute myocardial infarction (MI) and the plasma levels of MAp44 and its related proteins MASP-1 and MASP-3 in patients with first-time MI. In addition, we compared plasma levels of MAp44, MASP-1, and MASP-3 in MI patients to levels in a healthy control group.

AB - Many pathogenic processes and diseases are the result of an erroneous activation of the complement cascade and a number of inhibitors of complement have thus been examined for anti-inflammatory actions. It was recently demonstrated that supraphysiological concentrations of the endogenous complement inhibitor MAp44 (also denoted MAP1) protect against myocardial reperfusion injury. In the present study, we examined the association between outcome after acute myocardial infarction (MI) and the plasma levels of MAp44 and its related proteins MASP-1 and MASP-3 in patients with first-time MI. In addition, we compared plasma levels of MAp44, MASP-1, and MASP-3 in MI patients to levels in a healthy control group.

U2 - 10.1177/2048872613507004

DO - 10.1177/2048872613507004

M3 - Journal article

C2 - 24562799

SN - 2048-8726

VL - 3

SP - 3

EP - 9

JO - European Heart Journal: Acute Cardiovascular Care

JF - European Heart Journal: Acute Cardiovascular Care

IS - 1

ER -

Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater